Precision Biosciences Financials
This page shows Precision Biosciences (DTIL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Precision Biosciences has an operating margin of -152.2%, meaning the company retains $-152 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -38.1% the prior year.
Precision Biosciences's revenue declined 50.1% year-over-year, from $68.7M to $34.3M. This contraction results in a growth score of 0/100.
Precision Biosciences carries a low D/E ratio of 0.67, meaning only $0.67 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 88/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 13.32, Precision Biosciences holds $13.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Precision Biosciences generated -$65.8M in operating cash flow, capex of $85K consumed most of it, leaving -$65.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Precision Biosciences generates a -49.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 12.7% the prior year.
Precision Biosciences passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Precision Biosciences generates $1.44 in operating cash flow (-$65.8M OCF vs -$45.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Precision Biosciences earns $-36.7 in operating income for every $1 of interest expense (-$52.1M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Precision Biosciences generated $34.3M in revenue in fiscal year 2025. This represents a decrease of 50.1% from the prior year.
Precision Biosciences's EBITDA was -$50.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 122.7% from the prior year.
Precision Biosciences reported -$45.7M in net income in fiscal year 2025. This represents a decrease of 738.0% from the prior year.
Precision Biosciences earned $-3.56 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 442.3% from the prior year.
Cash & Balance Sheet
Precision Biosciences generated -$65.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 12.3% from the prior year.
Precision Biosciences held $110.8M in cash against $0 in long-term debt as of fiscal year 2025.
Precision Biosciences had 24M shares outstanding in fiscal year 2025. This represents an increase of 193.7% from the prior year.
Margins & Returns
Precision Biosciences's operating margin was -152.2% in fiscal year 2025, reflecting core business profitability. This is down 114.1 percentage points from the prior year.
Precision Biosciences's net profit margin was -133.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 143.9 percentage points from the prior year.
Precision Biosciences's ROE was -49.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 62.3 percentage points from the prior year.
Capital Allocation
Precision Biosciences invested $54.2M in research and development in fiscal year 2025. This represents a decrease of 9.0% from the prior year.
Precision Biosciences invested $85K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 66.0% from the prior year.
DTIL Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.2M+263007.7% | $13K-27.8% | $18K-37.9% | $29K-95.5% | $638K+10.8% | $576K-98.8% | $49.9M+183.8% | $17.6M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $14.5M+8.3% | $13.4M+4.6% | $12.8M-6.0% | $13.6M-14.6% | $15.9M+21.6% | $13.1M-24.0% | $17.2M+29.1% | $13.3M |
| SG&A Expenses | $7.2M-1.3% | $7.3M-19.7% | $9.1M+6.7% | $8.6M-10.7% | $9.6M+9.2% | $8.8M+2.8% | $8.5M+1.2% | $8.4M |
| Operating Income | $12.5M+160.5% | -$20.7M+5.5% | -$21.9M+1.1% | -$22.1M+11.0% | -$24.8M-16.8% | -$21.3M-188.1% | $24.1M+676.7% | -$4.2M |
| Interest Expense | $348K-3.9% | $362K+1.1% | $358K+1.1% | $354K-9.7% | $392K+53.1% | $256K-54.3% | $560K-2.4% | $574K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $20.1M+192.5% | -$21.8M+7.4% | -$23.5M-14.4% | -$20.6M-15.9% | -$17.7M-8.0% | -$16.4M-150.2% | $32.7M+281.3% | $8.6M |
| EPS (Diluted) | N/A | $-1.84+13.6% | $-2.13+3.6% | $-2.21 | N/A | $-2.25-148.2% | $4.67+174.7% | $1.70 |
DTIL Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $154.4M+65.1% | $93.5M-14.2% | $108.9M-12.4% | $124.4M-8.8% | $136.4M-11.0% | $153.3M-7.6% | $165.8M-10.3% | $184.7M |
| Current Assets | $118.7M+129.6% | $51.7M-26.4% | $70.3M-14.4% | $82.1M-13.6% | $95.0M-14.1% | $110.5M-23.3% | $144.0M-10.4% | $160.8M |
| Cash & Equivalents | $110.8M+147.0% | $44.9M-27.9% | $62.2M-19.4% | $77.2M-10.1% | $85.9M-13.0% | $98.8M-20.1% | $123.6M-10.3% | $137.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $0-100.0% | $4K | $0-100.0% | $4K-98.3% | $229K+21.8% | $188K-9.2% | $207K-46.9% | $390K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $62.2M-19.1% | $76.9M+2.7% | $74.9M-0.3% | $75.1M-6.2% | $80.0M-9.5% | $88.4M-3.0% | $91.1M-38.3% | $147.5M |
| Current Liabilities | $8.9M-40.6% | $15.0M+10.5% | $13.6M+9.5% | $12.4M-17.3% | $15.0M+25.0% | $12.0M-63.6% | $33.0M-1.1% | $33.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $92.2M+454.6% | $16.6M-51.2% | $34.1M-31.0% | $49.3M-12.5% | $56.4M-13.1% | $64.9M-13.2% | $74.7M+100.8% | $37.2M |
| Retained Earnings | -$528.2M+3.7% | -$548.3M-4.1% | -$526.5M-4.7% | -$503.0M-4.3% | -$482.5M-3.8% | -$464.7M-3.7% | -$448.3M+6.8% | -$481.0M |
DTIL Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.3M+26.3% | -$15.3M+24.7% | -$20.3M-6.4% | -$19.1M-2.0% | -$18.7M-216.0% | -$5.9M+60.2% | -$14.9M+21.7% | -$19.0M |
| Capital Expenditures | $19K | $0-100.0% | $2K-96.9% | $64K-34.0% | $97K+148.7% | $39K+39.3% | $28K-67.4% | $86K |
| Free Cash Flow | -$11.3M+26.2% | -$15.3M+24.7% | -$20.3M-6.1% | -$19.1M-1.8% | -$18.8M-215.6% | -$6.0M+60.1% | -$14.9M+21.9% | -$19.1M |
| Investing Cash Flow | -$325K-2011.8% | $17K+241.7% | -$12K+96.2% | -$314K-223.7% | -$97K-51.6% | -$64K-128.6% | -$28K-7.7% | -$26K |
| Financing Cash Flow | $77.5M+4572.5% | $1.7M-68.7% | $5.3M-50.4% | $10.7M+80.5% | $5.9M+58.6% | $3.7M+431.8% | $702K-98.2% | $40.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DTIL Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 36.6%+159013.5pp | -158976.9%-37438.0pp | -121538.9%-45290.6pp | -76248.3%-72353.9pp | -3894.4%-200.8pp | -3693.6%-3742.0pp | 48.4%+72.2pp | -23.8% |
| Net Margin | 58.9%+167535.8pp | -167476.9%-36810.3pp | -130666.7%-59752.9pp | -70913.8%-68132.4pp | -2781.3%+70.2pp | -2851.6%-2917.2pp | 65.6%+16.8pp | 48.8% |
| Return on Equity | 21.8%+152.7pp | -130.9%-61.8pp | -69.1%-27.4pp | -41.7%-10.2pp | -31.5%-6.2pp | -25.3%-69.2pp | 43.8%+20.8pp | 23.1% |
| Return on Assets | 13.0%+36.3pp | -23.3%-1.7pp | -21.6%-5.1pp | -16.5%-3.5pp | -13.0%-2.3pp | -10.7%-30.5pp | 19.8%+15.1pp | 4.7% |
| Current Ratio | 13.32+9.9 | 3.45-1.7 | 5.18-1.4 | 6.62+0.3 | 6.34-2.9 | 9.22+4.9 | 4.37-0.5 | 4.82 |
| Debt-to-Equity | 0.67-3.9 | 4.62+2.4 | 2.20+0.7 | 1.52+0.1 | 1.42+0.1 | 1.36+0.1 | 1.22-2.7 | 3.97 |
| FCF Margin | -33.0%+117428.6pp | -117461.5%-4833.8pp | -112627.8%-46710.5pp | -65917.2%-62973.7pp | -2943.6%-1910.4pp | -1033.2%-1003.3pp | -29.8%+78.6pp | -108.4% |
Similar Companies
Frequently Asked Questions
What is Precision Biosciences's annual revenue?
Precision Biosciences (DTIL) reported $34.3M in total revenue for fiscal year 2025. This represents a -50.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Precision Biosciences's revenue growing?
Precision Biosciences (DTIL) revenue declined by 50.1% year-over-year, from $68.7M to $34.3M in fiscal year 2025.
Is Precision Biosciences profitable?
No, Precision Biosciences (DTIL) reported a net income of -$45.7M in fiscal year 2025, with a net profit margin of -133.4%.
What is Precision Biosciences's EBITDA?
Precision Biosciences (DTIL) had EBITDA of -$50.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Precision Biosciences's operating margin?
Precision Biosciences (DTIL) had an operating margin of -152.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Precision Biosciences's net profit margin?
Precision Biosciences (DTIL) had a net profit margin of -133.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Precision Biosciences's return on equity (ROE)?
Precision Biosciences (DTIL) has a return on equity of -49.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Precision Biosciences's free cash flow?
Precision Biosciences (DTIL) generated -$65.9M in free cash flow during fiscal year 2025. This represents a -12.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Precision Biosciences's operating cash flow?
Precision Biosciences (DTIL) generated -$65.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Precision Biosciences's total assets?
Precision Biosciences (DTIL) had $154.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Precision Biosciences's capital expenditures?
Precision Biosciences (DTIL) invested $85K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Precision Biosciences spend on research and development?
Precision Biosciences (DTIL) invested $54.2M in research and development during fiscal year 2025.
What is Precision Biosciences's current ratio?
Precision Biosciences (DTIL) had a current ratio of 13.32 as of fiscal year 2025, which is generally considered healthy.
What is Precision Biosciences's debt-to-equity ratio?
Precision Biosciences (DTIL) had a debt-to-equity ratio of 0.67 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Precision Biosciences's return on assets (ROA)?
Precision Biosciences (DTIL) had a return on assets of -29.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Precision Biosciences's cash runway?
Based on fiscal year 2025 data, Precision Biosciences (DTIL) had $110.8M in cash against an annual operating cash burn of $65.8M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Precision Biosciences's Piotroski F-Score?
Precision Biosciences (DTIL) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Precision Biosciences's earnings high quality?
Precision Biosciences (DTIL) has an earnings quality ratio of 1.44x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Precision Biosciences cover its interest payments?
Precision Biosciences (DTIL) has an interest coverage ratio of -36.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Precision Biosciences?
Precision Biosciences (DTIL) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.